Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Orbimed Advisors Llc Insider Profile
32 Followers
Orbimed Advisors Llc, Shareholder at CTI BioPharma, holds 4.55M shares in Upstream Bio, Inc. (Ticker: UPB), holds 7.79M shares in Passage Bio (Ticker: PASG), holds 3.81M shares in MBX Biosciences, Inc. (Ticker: MBX).
Profitable Transactions
118 out of 206 Profitable Transactions
Average Return
+5.50%
Average return per transaction
Time Frame
Compare to
Insider Holdings
A breakdown of Orbimed Advisors Llc's holdings
Insider Roles
Roles that Orbimed Advisors Llc holds in companies
Most Profitable Insider Trade
Stock:
Sientra
(SIENQ)
(SIENQ)
Rating:Informative Buy
Date:Oct 28, 2014 - Oct 28, 2015
Return:+570.60%
The most profitable trade made by Orbimed Advisors Llc
Orbimed Advisors Llc's Trading History
CTI BioPharma
Jan 11, 2021
―
Informative Sell
7.00M
$68.36M
Intercept Pharma
Jul 21, 2015
―
Uninformative Buy
―
$21.29M
Repare Therapeutics
Sep 08, 2021
Shareholder
Uninformative Sell
274.79K
$9.43M
Acutus Medical
Jul 21, 2021
Director, Ten Percent Owner
Informative Buy
15.00M
$110.97K
CalciMedica
Sep 29, 2020
Ten Percent Owner
Uninformative Buy
―
$13.95M
PMV Pharmaceuticals
Nov 24, 2023
Ten Percent Owner
Informative Sell
195.76K
$10.30M
Prelude Therapeutics
May 24, 2023
Director, Ten Percent Owner
Informative Buy
5.00M
$10.22M
Galecto
Aug 17, 2023
Ten Percent Owner
Informative Sell
617.01K
$8.91M
Kinnate Biopharma
Apr 05, 2024
―
Uninformative Sell
―
$0.00
Terns Pharmaceuticals
Jul 17, 2024
Director, Ten Percent Owner
Informative Sell
561.64K
$4.47M
Decibel Therapeutics
Feb 19, 2021
―
Uninformative Buy
―
$4.34M
Edgewise Therapeutics
Jan 25, 2024
Director, Ten Percent Owner
Informative Buy
5.00M
$464.96M
Ikena Oncology
Sep 14, 2023
Director
Uninformative Buy
―
$13.32M
NeuroPace
May 03, 2024
Ten Percent Owner
Informative Sell
409.43K
$31.27M
Janux Therapeutics Inc
Dec 30, 2021
Director
Informative Sell
820.12K
$11.33M
Theseus Pharmaceuticals
Feb 14, 2024
―
Uninformative Sell
―
$0.00
Compass Therapeutics
Nov 10, 2022
Director, Ten Percent Owner
Informative Buy
1.29M
$26.68M
Third Harmonic Bio, Inc.
Sep 21, 2022
Director, Ten Percent Owner
Uninformative Buy
―
$72.01M
Verona Pharma
May 15, 2023
Director
Informative Sell
9.94M
$143.90M
Disc Medicine
Jun 20, 2024
Director
Informative Buy
3.00M
$14.02M
Turnstone Biologics Corp.
Jul 24, 2023
Director, Ten Percent Owner
Informative Buy
5.00M
$1.46M
ARS Pharmaceuticals
Aug 28, 2024
Director
Informative Sell
1.09M
$114.30M
ArriVent BioPharma, Inc.
Jan 31, 2024
Director, Ten Percent Owner
Uninformative Buy
―
$41.50M
MBX Biosciences, Inc.
Sep 17, 2024
Director, Ten Percent Owner
Uninformative Buy
―
$60.77M
Upstream Bio, Inc.
Oct 17, 2024
Director, Ten Percent Owner
Uninformative Buy
―
$103.58M
X4 Pharmaceuticals
Nov 20, 2017
Ten Percent Owner
Informative Buy
3.66M
$687.78K
scPharmaceuticals
Aug 15, 2024
Ten Percent Owner
Informative Buy
2.00M
$890.06K
Pieris Pharmaceuticals
May 02, 2018
See Remarks, Ten Percent Owner
Informative Sell
6.35M
$605.98K
Kala Pharmaceuticals
Feb 12, 2018
Ten Percent Owner
Informative Buy
323.25K
$22.29M
Synlogic
Apr 22, 2021
Director
Uninformative Buy
5.00M
$5.03M
Armo Biosciences Inc
Jun 22, 2018
―
Uninformative Sell
205.95M
$205.86M
Adicet Bio
Jan 26, 2024
Director, Ten Percent Owner
Informative Buy
7.50M
$3.02M
Audentes Therapeutics
Mar 12, 2018
―
Informative Sell
5.47M
$212.29M
Corvus Pharmaceuticals
Sep 22, 2021
Director, Ten Percent Owner
Informative Sell
6.76M
$58.33M
Rhythm Pharmaceuticals
May 24, 2018
See Remarks, Ten Percent Owner
Informative Sell
595.77K
$164.92M
Aadi Bioscience
Jul 02, 2018
Director, Ten Percent Owner
Informative Buy
2.99M
$11.48M
Constellation Pharmaceuticals
Jul 24, 2018
―
Uninformative Buy
―
$14.21M
Xtant Medical Holdings
Aug 17, 2022
Director, Ten Percent Owner
Uninformative Buy
―
$93.06K
Principia Biopharma
May 22, 2019
―
Informative Sell
30.25M
$160.65M
Guardant Health
Oct 11, 2018
Ten Percent Owner
Uninformative Buy
―
$275.26K
Logicbio Therapeutics
Oct 25, 2018
―
Uninformative Buy
―
$13.39M
Inspire Medical Systems
Aug 19, 2020
Director
Informative Sell
14.93M
$314.07K
Thoratec Corp
Dec 13, 2018
―
Uninformative Buy
―
$337.59M
Alector
Apr 16, 2020
Ten Percent Owner
Informative Sell
2.01M
$7.34M
Avedro
Feb 19, 2019
―
Uninformative Buy
―
$97.48M
Tricida
Nov 25, 2022
―
Informative Sell
2.21M
$0.00
Turning Point Therapeutics
Apr 24, 2019
―
Uninformative Buy
―
$154.11M
NextCure
May 13, 2019
Director, Ten Percent Owner
Informative Buy
5.25M
$3.55M
TELA Bio
Jul 02, 2024
Ten Percent Owner
Informative Sell
2.02M
$7.01M
89bio
Jan 27, 2022
Ten Percent Owner
Informative Sell
592.38K
$14.62M
Springworks Therapeutics
Sep 14, 2022
Ten Percent Owner
Informative Sell
4.92M
$212.40M
Prevail Therapeutics
Jun 26, 2019
―
Uninformative Buy
―
$317.92M
Alpine Immune Sciences
May 20, 2024
―
Uninformative Sell
―
$0.00
Sierra Oncology
Jul 01, 2022
―
Uninformative Sell
108.06M
$0.00
Arcutis Biotherapeutics
Jun 28, 2022
Ten Percent Owner
Informative Sell
7.29M
$4.19M
Passage Bio
Sep 23, 2024
Ten Percent Owner
Informative Sell
27.90K
$3.76M
Enliven Therapeutics
May 20, 2024
Director, Ten Percent Owner
Informative Sell
22.88M
$200.63M
Keros Therapeutics
Aug 15, 2024
Director
Informative Sell
11.00M
$6.41M
Oric Pharmaceuticals
Mar 31, 2021
Director
Uninformative Sell
2.43M
$19.67M
Adaptimmune Therapeutics
Jun 06, 2018
Director
Informative Sell
253.63K
$3.30M
Viewray
Aug 20, 2018
Ten Percent Owner
Informative Sell
5.19M
$835.40
Glaukos
Mar 06, 2018
Director
Informative Sell
26.79M
$0.00
Steadymed
Sep 07, 2018
―
Informative Sell
18.94M
$0.00
Nabriva Therapeutics
Dec 30, 2016
Director, Ten Percent Owner
Informative Buy
―
$50.95K
Spyre Therapeutics
Feb 21, 2017
Ten Percent Owner
Informative Buy
563.88K
$39.53M
Relypsa Inc
Jul 26, 2016
―
Informative Sell
129.39M
$236.73M
Mirati Therapeutics
Feb 05, 2015
―
Informative Buy
2.00M
$74.37M
Sientra
Oct 13, 2015
―
Informative Sell
1.72M
$427.50
Pacira Pharmaceuticals
Mar 13, 2012
Ten Percent Owner
Informative Sell
1.11M
$40.92M
Anthera Pharmaceuticals
Feb 01, 2013
Director
Informative Buy
3.76M
$223.86K
Otonomy
Nov 30, 2015
―
Informative Sell
1.94M
$212.76K
Insulet
―
Director
―
$411.02M
NxStage Medical
Dec 13, 2010
―
Informative Sell
53.25K
$80.71M
Loxo Oncology
Dec 12, 2017
―
Informative Sell
20.63M
$220.82M
Acceleron Pharma
Sep 26, 2013
―
Uninformative Buy
―
$103.12M
Supernus Pharmaceuticals
Feb 14, 2013
Ten Percent Owner
Informative Sell
2.28M
$29.03M
ChemoCentryx
Feb 15, 2012
―
Uninformative Buy
―
$47.23M
Albireo Pharma
Jun 11, 2009
―
Uninformative Sell
―
$65.60M
Sorrento Tech Inc
Oct 05, 2017
―
Informative Sell
137.10K
$19.75K
Athersys
Apr 29, 2011
Ten Percent Owner
Informative Sell
551.98K
$152.50
Amarin
Sep 05, 2012
Director
Uninformative Sell
3.37M
$2.79K
Avanir Pharmaceuticals
―
―
―
―
Complete Genomics
―
―
―
―
Given Imaging Ltd
―
―
―
―
Volcano Corp
―
―
―
―
Ambit
May 24, 2013
―
Informative Buy
233.37K
―
List of latest transactions for each holding click on a transaction to see Orbimed Advisors Llc's performance on stock
You May Also Like
Orbimed Advisors Llc insider profile FAQ
What is the percentage of profitable transactions made by Orbimed Advisors Llc?
The percentage of profitable transactions made by Orbimed Advisors Llc is 57%.
What is the average return per transaction made by Orbimed Advisors Llc?
The average return per transaction made by Orbimed Advisors Llc is 5.50%.
What stocks does Orbimed Advisors Llc hold?
Orbimed Advisors Llc holds: CTIC, ICPT, RPTX, AFIB, CALC, PMVP, PRLD, GLTO, KNTE, TERN, DBTX, EWTX, IKNA, NPCE, JANX, THRX, CMPX, THRD, VRNA, IRON, TSBX, SPRY, AVBP, MBX, UPB, XFOR, SCPH, PIRS, KALA, SYBX, ARMO, ACET, ~BOLD, CRVS, RYTM, AADI, CNST, XTNT, PRNB, GH, ~LOGC, INSP, ~THOR, ALEC, ~AVDR, TCDAQ, TPTX, NXTC, TELA, ETNB, SWTX, PRVL, ALPN, SRRA, ARQT, PASG, ELVN, KROS, ORIC, ADAP, VRAYQ, GKOS, STDY, NBRVF, SYRE, RLYP, MRTX, SIENQ, PCRX, ANTH, OTIC, PODD, NXTM, LOXO, XLRN, SUPN, CCXI, ALBO, ROKA, ATHXQ, AMRN, AVNR, ~GNOM, GIVN, VOLC, ~AMBI stocks.
What was Orbimed Advisors Llc’s latest transaction?
Orbimed Advisors Llc latest transaction was an Uninformative Buy of ―.
What was Orbimed Advisors Llc's most profitable transaction?
Orbimed Advisors Llc’s most profitable transaction was an Informative Buy of SIENQ stock on October 28, 2014. The return on the trade was 570.60%.
What is Orbimed Advisors Llc's role in CTI BioPharma?
Orbimed Advisors Llc's role in CTI BioPharma is Shareholder.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.